Holen Sie sich die Stockscreener-App
15.02
5.26%
0.75
Schlusskurs vom Vortag:
$14.27
Offen:
$14.14
24-Stunden-Volumen:
40,745
Relative Volume:
0.40
Marktkapitalisierung:
$222.49M
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.1266
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
+1.76%
1M Leistung:
+11.51%
6M Leistung:
-2.47%
1J Leistung:
+9.32%
1-Tages-Spanne:
$13.97
$15.18
1-Wochen-Bereich:
$13.97
$15.24
52-Wochen-Spanne:
$10.80
$17.79
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
15.02 | 222.49M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.69 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
541.99 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.66 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting - TipRanks
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Inhibrx announces leadership changes as co-founder departs - The Pharma Letter
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Stocks Rebound as US Government Shutdown Seems Averted - The Globe and Mail
When (INBX) Moves Investors should Listen - Stock Traders Daily
Simpson Thacher Adds Partner From Wilson Sonsini - Law360
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx’s early colorectal cancer data clouded by patient death - Endpoints News
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com Canada
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - insights.citeline.com
Trend Tracker for (INBX) - Stock Traders Daily
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - mx.advfn.com
James Sabry on industry-shaping changes in innovation and deal-making - biocentury.com
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com UK
Inhibrx: The Biotech Spinoff Poised For Big Gains - Forbes
Inhibrx CEO Mark Lappe buys $596,762 worth of company stock - Investing.com
Hedge Fund and Insider Trading News: Boaz Weinstein, Bill Ackman, Third Point, AQR Capital Management, Inhibrx Biosciences Inc (INBX), Comstock Resources Inc (CRK), and More - Insider Monkey
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Finansavisen
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibrx Biosciences Inc-Aktie (INBX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kayyem Jon Faiz | Director |
Nov 20 '24 |
Buy |
14.19 |
37,500 |
532,204 |
69,843 |
| Lappe Mark | Chief Executive Officer |
Sep 12 '24 |
Buy |
15.05 |
26,963 |
405,793 |
692,511 |
| Lappe Mark | Chief Executive Officer |
Sep 16 '24 |
Buy |
17.13 |
13,037 |
223,324 |
705,548 |
| Vuori Kristiina MD | Director |
Sep 11 '24 |
Buy |
15.07 |
6,457 |
97,307 |
13,776 |
| Vuori Kristiina MD | Director |
Sep 10 '24 |
Buy |
15.00 |
179 |
2,685 |
7,319 |
| Lappe Mark | Chief Executive Officer |
Sep 06 '24 |
Buy |
15.29 |
26,000 |
397,540 |
647,548 |
| Lappe Mark | Chief Executive Officer |
Sep 09 '24 |
Buy |
15.21 |
9,500 |
144,495 |
657,048 |
| Lappe Mark | Chief Executive Officer |
Sep 10 '24 |
Buy |
15.19 |
8,500 |
129,115 |
665,548 |
| Lappe Mark | Chief Executive Officer |
Sep 03 '24 |
Buy |
15.81 |
20,000 |
316,263 |
165,000 |
| Lappe Mark | Chief Executive Officer |
Aug 29 '24 |
Buy |
14.03 |
10,000 |
140,300 |
135,000 |
1.77%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):